Signaturefd, LLC Amicus Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 236 shares of FOLD stock, worth $2,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares

236

Previous 236 -0.0%

Holding current value

$2,242

Previous $2,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$9.04 - $11.75 $922 - $1,198	102 Added 76.12%	236 $2,000
Q1 2024 May 03, 2024	SELL	$11.43 - $14.24 $1,051 - $1,310	-92 Reduced 40.71%	134 $1,000
Q4 2023 Jan 31, 2024	SELL	$9.97 - $14.52 $7,567 - $11,020	-759 Reduced 77.06%	226 $3,000
Q3 2023 Nov 03, 2023	SELL	$11.78 - $13.86 $2,850 - $3,354	-242 Reduced 19.72%	985 $11,000
Q2 2023 Aug 01, 2023	BUY	$10.72 - $13.3 $10,762 - $13,353	1,004 Added 450.22%	1,227 $15,000
Q1 2023 Apr 28, 2023	BUY	$10.91 - $13.54 $840 - $1,042	77 Added 52.74%	223 $2,000
Q4 2022 Jan 27, 2023	BUY	$9.89 - $12.7 $642 - $825	65 Added 80.25%	146 $1,000
Q2 2022 Aug 10, 2022	BUY	$6.23 - $11.12 $504 - $900	81 New	81 $1,000
Q1 2022 May 02, 2022	SELL	$7.89 - $12.48 $646 - $1,023	-82 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$8.74 - $11.84 $1,319 - $1,787	-151 Reduced 64.81%	82 $1,000
Q1 2021 Apr 30, 2021	SELL	$9.2 - $23.86 $331 - $858	-36 Reduced 13.38%	233 $2,000
Q3 2020 Nov 03, 2020	BUY	$12.89 - $15.89 $464 - $572	36 Added 15.45%	269 $4,000
Q1 2020 Apr 23, 2020	BUY	$6.63 - $11.16 $543 - $915	82 Added 54.3%	233 $2,000
Q4 2019 Feb 05, 2020	BUY	$7.48 - $10.75 $1,129 - $1,623	151 New	151 $1,000

Others Institutions Holding FOLD

# of Institutions

313

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.66B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account